AQUILA BIOPHARMACEUTICALS INC

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Certification of termination of registration of a class of securities (Section 12(g))

General form for quarterly reports under Section 13 or 15(d)

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Written communication about a business combination transaction (Rule 425)

1

Written communication about a business combination transaction (Rule 425)

Definitive Proxy Statement

Written communication about a business combination transaction (Rule 425)

General form for quarterly reports under Section 13 or 15(d)

1

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

5,7

General form for quarterly reports under Section 13 or 15(d)

Registration statement under Securities Act of 1933

Definitive Proxy Statement

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

No description available

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

General form for quarterly reports under Section 13 or 15(d)

General form for quarterly reports under Section 13 or 15(d)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Prospectus filed under Rule 424(b)(1)

Registration statement under Securities Act of 1933 (amendment)

No description available

Registration statement under Securities Act of 1933

No description available

General form for quarterly reports under Section 13 or 15(d)

Definitive Proxy Statement

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

No description available

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

General form for quarterly reports under Section 13 or 15(d)

No description available

5

No description available

General form for quarterly reports under Section 13 or 15(d)

5

No description available

General form for quarterly reports under Section 13 or 15(d)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Registration statement under Securities Act of 1933 (amendment)

2,7

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Definitive Proxy Statement

No description available

Registration statement under Securities Act of 1933

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

General form for quarterly reports under Section 13 or 15(d)

General form for quarterly reports under Section 13 or 15(d)

5

5

General form for quarterly reports under Section 13 or 15(d)

Additional Information for Proxy Statement/ Votes

Annual Report Scanned (Paper)

Definitive Proxy Statement

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

No description available

General form for quarterly reports under Section 13 or 15(d)

2,5,7

General form for quarterly reports under Section 13 or 15(d)

Current report pursuant to Section 13 or 15(d)

Current report pursuant to Section 13 or 15(d)

Current report pursuant to Section 13 or 15(d)

General form for quarterly reports under Section 13 or 15(d)

Current report pursuant to Section 13 or 15(d)

5,7

5,7

5,7

5,7

5,7

5,7

5,7

AQUILA BIOPHARMACEUTICALS INC